CPHI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Home Conference & Exhibition News Pfizer to present new data on Xeljanz for ulcerative colitis at UEG Week 2016
News
16 Oct 2016

Pfizer to present new data on Xeljanz for ulcerative colitis at UEG Week 2016

Includes an oral presentation looking at the effect of prior treatment with tumour necrosis factor inhibitors on efficacy endpoints.

Pfizer has announced that three abstracts for Xeljanz (tofacitinib citrate), being investigated in moderate to severe ulcerative colitis (UC), will be presented at the upcoming United European Gastroenterology Week (UEG Week 2016), 15-19 October in Vienna, Austria. The tofacitinib presentations will highlight new research results from the Phase III Oral Clinical Trials for tofAcitinib in ulceratiVE colitis (OCTAVE) Induction trials, including one oral presentation looking at the effect of prior treatment with tumour necrosis factor inhibitors (TNFi) on efficacy endpoints. In addition, two abstracts have been accepted as poster presentations, highlighting results by endoscopic response, and onset of action, respectively.

“The new data to be presented at UEG Week deepen our understanding of the efficacy and safety profile of tofacitinib in ulcerative colitis,” said Michael Corbo, Chief Development Officer, Inflammation & Immunology, Pfizer Inc. “We know there is a significant unmet need in the UC community for additional treatment options and, if approved, tofacitinib may have the potential to offer patients and their physicians an oral treatment option that could address these unmet needs in the course of the disease.”

Tofacitinib is the first in a new class of medicines called Janus kinase (JAK) inhibitors under investigation for the treatment of moderate to severe UC. Tofacitinib is a small molecule taken as a pill. It acts on specific inflammatory responses thought to play a role in the inflammation associated with UC.

Oral Presentation

  • 1. Tofacitinib has induction efficacy in moderately to severely active ulcerative colitis, regardless of prior TNF inhibitor therapy (#OP106, Session: 504 – Future drugs in IBD, Monday, October 17, 15:45 – 17:15, Room C)

    • Poster Presentations

  • 2. Tofacitinib for induction therapy in patients with active ulcerative colitis in two phase 3 clinical trials: results by local and central endoscopic assessments (#P0306, Poster Session: IBD I, Monday, October 17, 10:30 – 17:00, Poster Exhibition – Hall X4 & X5)

  • 3. Onset of efficacy of tofacitinib for induction therapy in patients with active ulcerative colitis in two multinational, phase 3 clinical trials (#P0842, Poster Session: IBD II Tuesday, October 18, 09:00 – 17:00, Poster Exhibition – HALL X4 & X5)

    • Related tags
    Conference & Exhibition Research & Development

    Related News